Bank Of New York Mellon Corp Icosavax, Inc. Transaction History

Bank Of New York Mellon Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$5.62 - $11.51 $390,219 - $799,185	69,434 New	69,434 $403 Million
Q4 2022 Feb 14, 2023	BUY	$2.32 - $10.97 $163,300 - $772,156	70,388 New	70,388 $558,000
Q3 2022 Nov 14, 2022	BUY	$3.09 - $9.21 $21,543 - $64,212	6,972 Added 12.03%	64,907 $205,000
Q2 2022 Aug 15, 2022	SELL	$5.7 - $10.33 $33,664 - $61,008	-5,906 Reduced 9.25%	57,935 $332,000
Q1 2022 May 11, 2022	BUY	$4.41 - $22.5 $113,517 - $579,172	25,741 Added 67.56%	63,841 $449,000
Q4 2021 Feb 11, 2022	BUY	$21.07 - $34.98 $115,442 - $191,655	5,479 Added 16.8%	38,100 $872,000
Q3 2021 Nov 12, 2021	BUY	$24.85 - $40.25 $810,631 - $1.31 Million	32,621 New	32,621 $965,000

1.37M

Ticker ICVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,885,200
Description
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.